Income Statement Palvella Therapeutics, Inc.

Equities

PVLA

US6979471090

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-13 pm EDT			5-day change	1st Jan Change
122.06 ^USD	-10.64%		-9.17%	+16.61%

Mar. 02	Palvella Therapeutics Insider Bought Shares Worth $300,000, According to a Recent SEC Filing	MT
Mar. 02	Palvella Therapeutics Insider Bought Shares Worth $500,000, According to a Recent SEC Filing	MT

4207819d98912e9ca5446aad3b3.GuLYsh39APWKu5d2zYgvTRzRCa2PLuEa87oxk4mWtwc.V6OXwSWUUZDs3_E_-uN_Ok_jc_voZ4hQn9R43cD1j2op27bnd7JJrN3R3g

Published financial data: PALVELLA THERAPEUTICS, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2022	2023	2024
Selling General & Admin Expenses, Total	4.16M	3.08M	5.94M
R&D Expenses	13.88M	8.79M	8.15M
Other Operating Expenses, Total	18.04M	11.87M	14.1M
Operating Income	-18.04M	-11.87M	-14.1M
Interest Expense, Total	-10.36M	-	-4.32M
Interest And Investment Income	-	6.26M	-
Net Interest Expenses	-10.36M	6.26M	-4.32M
Other Non Operating Income (Expenses)	-174K	1.2M	-122K
EBT, Excl. Unusual Items	-28.58M	-4.41M	-18.53M
Other Unusual Items	-	23.1M	1.1M
EBT, Incl. Unusual Items	-28.58M	18.69M	-17.43M
Income Tax Expense	-1.03M	-	-
Earnings From Continuing Operations	-27.55M	18.69M	-17.43M
Net Income to Company	-27.55M	18.69M	-17.43M
Net Income - (IS)	-27.55M	18.69M	-17.43M
Preferred Dividend and Other Adjustments	-	14.81M	-
Net Income to Common Incl Extra Items	-27.55M	3.88M	-17.43M
Net Income to Common Excl. Extra Items	-27.55M	3.88M	-17.43M
Per Share Items
Net EPS - Basic	-4.82	0.68	-7.83
Basic EPS - Continuing Operations	-4.82	0.68	-7.83
Basic Weighted Average Shares Outstanding	5.72M	5.72M	2.23M
Net EPS - Diluted	-4.82	0.67	-7.83
Diluted EPS - Continuing Operations	-4.82	0.67	-7.83
Diluted Weighted Average Shares Outstanding	5.72M	5.8M	2.23M
Normalized Basic EPS	-3.12	-0.48	-5.2
Normalized Diluted EPS	-3.12	-0.48	-5.2
Supplemental Items
EBITA	-18.04M	-11.87M	-14.1M
EBIT	-18.04M	-11.87M	-14.1M
Effective Tax Rate - (Ratio)	3.59	-	-
Normalized Net Income	-17.86M	-2.75M	-11.58M
Supplemental Operating Expense Items
General and Administrative Expenses	4.16M	3.08M	5.94M
Research And Development Expense From Footnotes	13.88M	8.79M	8.15M
Net Rental Expense, Total	80K	80K	-
Stock-Based Comp., R&D Exp. (Total)	347K	548K	569K
Stock-Based Comp., G&A Exp. (Total)	80K	55K	261K
Total Stock-Based Compensation	427K	603K	830K

Fiscal Period: December	2022	2023	2024
Assets
Cash And Equivalents	16.05M	7.35M	83.6M
Total Cash And Short Term Investments	16.05M	7.35M	83.6M
Accounts Receivable, Total	-	-	358K
Other Receivables	-	-	1.98M
Total Receivables	-	-	2.34M
Prepaid Expenses	471K	198K	2.3M
Total Current Assets	16.52M	7.55M	88.23M
Total Assets	16.52M	7.55M	88.23M
Liabilities
Accounts Payable, Total	3.18M	936K	4.59M
Accrued Expenses, Total	2.44M	1.26M	4.28M
Other Current Liabilities	159K	169K	3.17M
Total Current Liabilities	5.78M	2.36M	12.04M
Long-Term Debt	32.42M	8.05M	11.94M
Other Non Current Liabilities	1.5M	1.01M	1.65M
Total Liabilities	39.7M	11.43M	25.63M
Preferred Stock Convertible	70.6M	70.6M	-
Total Preferred Equity	70.6M	70.6M	-
Common Stock, Total	-	-	11K
Additional Paid In Capital	1.22M	1.82M	156M
Retained Earnings	-94.99M	-76.3M	-93.74M
Comprehensive Income and Other	-	-	3K
Total Common Equity	-93.78M	-74.48M	62.61M
Total Equity	-23.17M	-3.88M	62.61M
Total Liabilities And Equity	16.52M	7.55M	88.23M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	5.72M	5.72M	11.02M
ECS Total Common Shares Outstanding	5.72M	5.72M	11.01M
Book Value / Share	-16.4	-13.02	5.69
Tangible Book Value	-93.78M	-74.48M	62.61M
Tangible Book Value Per Share	-16.4	-13.02	5.69
Total Debt	32.42M	8.05M	11.94M
Net Debt	16.36M	704K	-71.66M
Debt Equivalent Oper. Leases	640K	640K	-
Account Code - Inventory Valuation	-	3	3
Full Time Employees	-	-	14

Fiscal Period: December	2022	2023	2024
Net Income	-27.55M	18.69M	-17.43M
Stock-Based Compensation (CF)	427K	603K	830K
Other Operating Activities, Total	10.66M	-29.85M	5.96M
Change In Accounts Payable	1.98M	-2.24M	2.24M
Change in Other Net Operating Assets	-359K	-904K	-2.43M
Cash from Operations	-14.84M	-13.7M	-10.84M
Long-Term Debt Issued, Total	-	5M	18.43M
Total Debt Issued	-	5M	18.43M
Issuance of Common Stock	34K	-	60M
Issuance of Preferred Stock	9.53M	-	-
Other Financing Activities, Total	-	-	8.66M
Cash from Financing	9.57M	5M	87.09M
Foreign Exchange Rate Adjustments	-	-	3K
Net Change in Cash	-5.27M	-8.7M	76.25M
Supplemental Items
Levered Free Cash Flow	-	-9.96M	-5.43M
Unlevered Free Cash Flow	-	-9.96M	-2.74M
Change In Net Working Capital	-	3.15M	-5.24M
Net Debt Issued / Repaid	-	5M	18.43M

Fiscal Period: December	2022	2023	2024
Profitability
Return on Assets	-	-61.63	-18.39
Return on Total Capital	-	-110.58	-22.38
Return On Equity %	-	-138.18	-59.37
Return on Common Equity	-	-4.62	293.6
Short Term Liquidity
Current Ratio	2.86	3.2	7.33
Quick Ratio	2.78	3.11	7.14
Operating Cash Flow to Current Liabilities	-2.57	-5.81	-0.9
Long Term Solvency
Total Debt/Equity	-139.89	-207.58	19.07
Total Debt / Total Capital	350.72	192.96	16.02
LT Debt/Equity	-139.89	-207.58	19.07
Long-Term Debt / Total Capital	350.72	192.96	16.02
Total Liabilities / Total Assets	240.24	151.4	29.04
EBIT / Interest Expense	-1.74	-	-3.26
Growth Over Prior Year
EBITA, 1 Yr. Growth %	-	-34.21	18.75
EBIT, 1 Yr. Growth %	-	-34.21	18.75
Earnings From Cont. Operations, 1 Yr. Growth %	-	-167.84	-193.27
Net Income, 1 Yr. Growth %	-	-167.84	-193.27
Normalized Net Income, 1 Yr. Growth %	-	-84.58	320.56
Diluted EPS Before Extra, 1 Yr. Growth %	-	-113.9	-460.93
Total Assets, 1 Yr. Growth %	-	-54.32	1.07K
Tangible Book Value, 1 Yr. Growth %	-	-20.57	-184.06
Common Equity, 1 Yr. Growth %	-	-20.57	-184.06
Cash From Operations, 1 Yr. Growth %	-	-7.66	-20.89
Levered Free Cash Flow, 1 Yr. Growth %	-	-	-45.47
Unlevered Free Cash Flow, 1 Yr. Growth %	-	-	-72.55
Compound Annual Growth Rate Over Two Years
EBITA, 2 Yr. CAGR %	-	-	-11.61
EBIT, 2 Yr. CAGR %	-	-	-11.61
Earnings From Cont. Operations, 2 Yr. CAGR %	-	-	-20.45
Net Income, 2 Yr. CAGR %	-	-	-20.45
Normalized Net Income, 2 Yr. CAGR %	-	-	-19.47
Diluted EPS Before Extra, 2 Yr. CAGR %	-	-	27.47
Total Assets, 2 Yr. CAGR %	-	-	131.08
Tangible Book Value, 2 Yr. CAGR %	-	-	-18.29
Common Equity, 2 Yr. CAGR %	-	-	-18.29
Cash From Operations, 2 Yr. CAGR %	-	-	-14.53